Management of Deruxtecan-Induced Interstitial Lung Disease
Immediately discontinue deruxtecan and initiate corticosteroid therapy for any grade of ILD/pneumonitis, with permanent discontinuation required for grade ≥3 events. 1
Monitoring and Early Detection
Routine CT surveillance every 6-12 weeks is mandatory while on deruxtecan therapy, as ILD typically develops after a median of 5.1 months (range 0.5-17.3 months) from treatment initiation 1, 2. The most common radiographic pattern is cryptogenic organizing pneumonia (COP) in 72% of cases, though acute interstitial pneumonia/ARDS pattern (11%) indicates severe, potentially fatal disease requiring immediate intervention 3.
High-Risk Patient Identification
Do not use deruxtecan in patients with:
- History of noninfectious ILD requiring steroid therapy
- Prior clinically significant pneumonitis from immune checkpoint inhibitors or other anticancer therapies
- Evidence of ILD on baseline imaging 1
Exercise extreme caution in patients with:
- Male sex
- BMI ≥21.3 kg/m²
- Impaired renal function
- Baseline oxygen saturation <95%
- Moderate/severe lung comorbidities 1, 2
Treatment Algorithm by ILD Grade
Grade 1 (Asymptomatic or Mild Symptoms)
- Withhold deruxtecan immediately
- Initiate oral corticosteroids (specific dosing per institutional protocols)
- Monitor with serial CT imaging
- If resolves within 7 days: may resume same dose
- If takes >7 days: dose reduction required upon resumption 1, 4
Grade 2 (Moderate Symptoms)
- Discontinue deruxtecan
- Initiate systemic corticosteroids (typically prednisone 0.5-1.0 mg/kg/day) 5
- Consider hospitalization for monitoring
- Permanent discontinuation is recommended, though rechallenge at reduced dose may be considered in select cases after complete resolution 1, 4
Grade 3-4 (Severe or Life-Threatening)
- Permanently discontinue deruxtecan
- Hospitalize immediately
- High-dose IV methylprednisolone
- Provide supplemental oxygen or mechanical ventilation as needed
- If no improvement after 48 hours on corticosteroids, consider adding infliximab, mycophenolate mofetil, or IV immunoglobulin 5
- Never rechallenge with deruxtecan 1
Grade 5 (Fatal)
- Most commonly associated with AIP/ARDS radiographic pattern
- Occurs in approximately 1% of patients
- Earlier onset (median 17.9 weeks vs 32.7 weeks for other patterns) 3, 6
Critical Management Principles
The diagnosis is one of exclusion—you must rule out infection, disease progression, radiation pneumonitis, and other causes before attributing ILD to deruxtecan 7. This requires clinical evaluation, imaging, and often bronchoscopy with bronchoalveolar lavage.
Corticosteroid therapy is the cornerstone of treatment for symptomatic ILD (grade ≥2), though evidence for its efficacy comes primarily from observational data rather than controlled trials 5, 8. Most patients (87%) respond to withholding deruxtecan with or without corticosteroids 3.
Patient Education Requirements
Educate all patients starting deruxtecan to immediately report:
- New or worsening cough
- Dyspnea or shortness of breath
- Fever without clear infectious source
- Any respiratory symptoms 9, 7
Early symptom recognition by patients is essential, as delayed diagnosis correlates with higher severity, less reversibility, and residual fibrotic lung damage 5.
Antiemetic Prophylaxis
While managing ILD, continue appropriate supportive care. For nausea/vomiting (occurs in 73% of patients), use three-drug prophylaxis: 5-HT3 receptor antagonist + dexamethasone + neurokinin-1 receptor antagonist 1.
Key Pitfall to Avoid
The most critical error is continuing deruxtecan after ILD symptoms develop. The AIP/ARDS pattern has significantly higher mortality and requires immediate recognition—look for rapid onset, severe hypoxemia, and diffuse ground-glass opacities on CT 3. Any delay in discontinuation and corticosteroid initiation worsens outcomes and increases the risk of irreversible fibrosis or death.